Fortress Biotech Inc FBIO.OQ FBIO.O is expected to show a fall in quarterly revenue when it reports results on November 15 (estimated) for the period ending September 30 2024
The Bay Harbor Islands Florida-based company is expected to report a 7.3% decrease in revenue to $32.218 million from $34.75 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Fortress Biotech Inc is for a loss of 59 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Fortress Biotech Inc is $13.00, above its last closing price of $1.70.
This summary was machine generated November 13 at 15:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments